Effects of High-Dose Methylprednisolone Therapy on Coagulation Factors in Patients with Acute Immune Thrombocytopenic Purpura

Abstract

Autoimmune thrombocytopenic purpura (ITP) is a disease that presents with skin and mucous membrane bleeding due to thrombocytopenia. In the literature, there are a few studies about the effect of high-dose steroid therapy on coagulation tests in different diseases, but their results are still controversial. In this study, coagulation parameters were investigated that might have a role in hemostatic compensation in childhood acute ITP before and after high-dose methylprednisolone (HDMP) treatment. The study includes 21 children age 1.5 to 14 years with acute ITP and 21 healthy age-matched control subjects. All patients with acute ITP received HDMP for 7 days. Before and after HDMP treatment (0 and 8 days) prothrombin time, partial thromboplastin time, fibrinogen, Protein C, Protein S, antithrombin III, and the levels of factor II (FII), FV, FVII, FVIII, FIX, FX, FXI, and FXII were studied in all subjects. The results were compared with those of the control group. Pre-treatment Protein C and Protein S levels in the patient group were significantly lower than those in the control groups (p<0.05). Protein S and Protein C levels were significantly improved after HDMP treatment in patient group. There were lower FV, FVII, FX values in the patient group compared to the control groups on admission. There was no difference in AT III and fibrinogen levels before and after treatment. As a result, some changes in the coagulation system associated with thrombocytopenia were observed in patients with acute ITP. These changes may be accepted as compensatory mechanisms to maintain hemostasis.

Keywords

Autoimmune thrombocytopenic purpura Methylprednisolone Coagulation test

References

McClure PD . Idiopathic thrombocytopenic purpura in children: Diagnosis and management. Pediatrics 1975;55:68.

Mizutani H , Furubayashi T , Imai Y , et al. Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): Experimental studies using ITP-prone mice, (NZW x BXSB) F1. Blood 1992;79:942.

Oner AF , Gurgey A , Kirazli S , et al. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase. Leuk Lymphoma 1999;33:361.

Jorgensen KA , Sorensen P , Freund L. Effect of glucocorticosteroids on some coagulation tests. Acta Haematol 1982;68:39.

Mall V , Thomas KB , Sauter S , et al. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia. Klin Padiatr 1999;211:205.

Dreyfuss F , Menczel J. The effect of corticotrophin, cortisone, and prednisone on whole blood coagulation time. J Lab Clin Med 1958;51:530.

Sere KM , Hackeng TM . Basic mechanisms of hemostasis. Semin Vasc Med 2003;3:3.

Butros LJ , Bussel JB . Intracranial hemorrhage in immune thrombocytopenic purpura: A retrospective analysis. J Pediatr Hematol Oncol 2003;25:660.

Teitel JM . Unexpected bleeding disorders: Algorithm for approach to therapy. Clin Lab Haematol 2000;22:26.

10.

Poujol-Robert A , Rosmorduc O , Serfaty L , et al. Genetic and acquired thrombotic factors in chronic hepatitis C. Am J Gastroenterol 2004;99:527.

11.

Slofstra SH , Spek CA , ten Cate H. Disseminated intravascular coagulation. Hematol J 2003;4:295.

12.

Ware LB , Fang X , Matthay MA . Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003;285:514.

13.

Matthay MA , Ware LB . Plasma protein C levels in patients with acute lung injury: Prognostic significance. Crit Care Med 2004;32:229.

14.

Mori Y , Wada H , Okugawa Y , et al. Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Clin Appl Thromb Hemost 2001;7:5.

15.

Bayazit AK , Kilinc Y. Natural coagulation inhibitors (protein C, protein S, antithrombin) in patients with sickle cell anemia in a steady state. Pediatr Int 2001;43:592.

16.

Priest JR , Ramsay NK , Latchaw RE , et al. Thrombotic and hemorrhagic strokes complicating early therapy for childhood acute lymphoblastic leukemia. Cancer 1980;46:1548.

17.

Nowak-Gottl U , Heinecke A , von Kries R , et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: Impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001;103:165.

18.

Seifter EJ , Brooks BJ Jr , Urba WJ . Possible interactions between warfarin and antineoplastic drugs. Cancer Treat Rep 1985;69:244.

19.

Tracy PB , Mann KG . Abnormal formation of the prothrombinase complex: Factor V deficiency and related disorders. Hum Pathol 1987;18:162.

20.

Takaku T , Kuriyama Y , Shoji N , et al. Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis. Rinsho Ketsueki 2002;43:1050.